Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib plus Venetoclax Arm of the FLAIR Trial

被引：1

作者：

Rawstron, Andy ^{[1
]}

Webster, Nichola ^{[1
,2
]}

Dalal, Surita ^{[1
,2
]}

de Tute, Ruth M. ^{[1
]}

Bell, Sue ^{[3
]}

Cairns, David Allan ^{[3
]}

Girvan, Sean ^{[3
]}

Greatorex, Natasha ^{[3
]}

Hockaday, Anna ^{[3
]}

Jackson, Sharon ^{[3
]}

Phillips, David ^{[3
]}

Stones, David ^{[3
]}

Allsup, David ^{[4
]}

Bloor, Adrian John Clifton ^{[5
]}

Sarma, Anita ^{[1
]}

Varghese, Abraham Mullasseril ^{[6
]}

Munir, Talha ^{[7
]}

Hillmen, Peter ^{[8
]}

机构：

[1] Leeds Teaching Hosp NHS Trust, Leeds Canc Ctr, HMDS, Leeds, W Yorkshire, England

[2] Univ Leeds, Leeds Inst Med Res, Leeds, W Yorkshire, England

[3] Univ Leeds, Leeds Inst Clin Trials Res, Leeds Canc Res UK Clin Trials Unit, Leeds, W Yorkshire, England

[4] Castle Hill Hosp, Cottingham, England

[5] Christie NHS Fdn Trust, Haematol & Transplant Unit, Manchester, Lancs, England

[6] Leeds Teaching Hosp NHS Trust, Dept Haematol, Leeds Canc Ctr, Leeds, W Yorkshire, England

[7] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[8] St James Univ Hosp, Leeds Inst Med Res, Leeds, W Yorkshire, England

来源：

关键词：

D O I：

10.1182/blood-2023-187943

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 2 条